Hsu, S. D., Acharya, C. R., Riedel, R. F., Redman, R. C., Garman, K. S., Dressman, H. K., … Potti, A. (2008). Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2–8, and PAX9, to predict prognosis and guide therapeutic strategies. Journal of Clinical Oncology, 26(15_suppl), 7511–7511. https://doi.org/10.1200/jco.2008.26.15_suppl.7511

Hsu, S. D., C. R. Acharya, R. F. Riedel, R. C. Redman, K. S. Garman, H. K. Dressman, G. Ginsburg, S. Powers, D. Mu, and A. Potti. “Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2–8, and PAX9, to predict prognosis and guide therapeutic strategies.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 7511–7511. https://doi.org/10.1200/jco.2008.26.15_suppl.7511.

Hsu SD, Acharya CR, Riedel RF, Redman RC, Garman KS, Dressman HK, et al. Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2–8, and PAX9, to predict prognosis and guide therapeutic strategies. Journal of Clinical Oncology. 2008 May 20;26(15_suppl):7511–7511.

Hsu, S. D., et al. “Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2–8, and PAX9, to predict prognosis and guide therapeutic strategies.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 7511–7511. Crossref, doi:10.1200/jco.2008.26.15_suppl.7511.

Hsu SD, Acharya CR, Riedel RF, Redman RC, Garman KS, Dressman HK, Ginsburg G, Powers S, Mu D, Potti A. Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2–8, and PAX9, to predict prognosis and guide therapeutic strategies. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):7511–7511.